Study S000367
A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity Without Type 2 Diabetes
Registration
Registered primary outcomes
- Percentage change in body weight from baseline to Week 76 [Baseline and at Week 76]
- Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76 [Baseline and at Week 76]
Linked records (4)
Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
| Record | Title | Year | Design | Identifiers | Link basis |
|---|---|---|---|---|---|
| R0008183 | Survodutide Once Weekly for the Treatment of Adults with Obesity. le Roux CW, The New England journal of medicine | 2026 | Randomized trial | PMID 42253238DOI | cites ClinicalTrials.gov:NCT06066515; registry reference DERIVED:42253238 |
| R0013478 | Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1). le Roux CW, Diabetes, obesity & metabolism | 2026 | Randomized trial | PMID 41187967DOI | cites ClinicalTrials.gov:NCT06066515; registry reference DERIVED:41187967 |
| R0056531 | Essai de phase 3 du survodutide administré une fois par semaine pour le traitement de l’obésité chez l’adulte : SYNCHRONIZE™-1 Emmanuel Disse, Annales d Endocrinologie | 2026 | Other trial | DOI | cites ClinicalTrials.gov:NCT06066515 |
| R0015290 | Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2). Wharton S, Obesity (Silver Spring, Md.) | 2025 | Protocol | PMID 39495965DOI | cites ClinicalTrials.gov:NCT06066515 |